Edition:
India

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

24.58USD
2:29am IST
Change (% chg)

$1.00 (+4.24%)
Prev Close
$23.58
Open
$23.60
Day's High
$25.40
Day's Low
$23.60
Volume
343,386
Avg. Vol
369,862
52-wk High
$32.22
52-wk Low
$16.51

Select another date:

Mon, Jan 8 2018

BRIEF-Flexion Therapeutics Announces Initial Data From Clinical Trial Evaluating Repeat Administration Of Zilretta

* FLEXION THERAPEUTICS ANNOUNCES INITIAL DATA FROM CLINICAL TRIAL EVALUATING REPEAT ADMINISTRATION OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION)

BRIEF-Flexion Therapeutics Enrolls First Patient In Phase 2 Pharmacokinetics And Safety Study Of Zilretta

* FLEXION THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 2 PHARMACOKINETICS AND SAFETY STUDY OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) IN BILATERAL OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

BRIEF-Flexion therapeutics reports third-quarter results

* Flexion Therapeutics reports third-quarter 2017 financial results and recent business highlights

BRIEF-Flexion Therapeutics announces pricing of public offering of common stock

* Flexion Therapeutics announces pricing of public offering of common stock

BRIEF-Flexion Therapeutics- Proposed public offering of 4 mln common shares

* Flexion Therapeutics announces proposed public offering of common stock

Flexion's knee pain drug gets FDA nod, shares hit life high

Flexion Therapeutics Inc said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer's shares soaring to a record high in regular trading on Friday.

UPDATE 2-Flexion's knee pain drug gets FDA nod, shares hit life high

* Osteoarthritis drug market to hit $3.5 bln by 2026 - GlobalData

BRIEF-Flexion Therapeutics announces FDA approval of Zilretta for osteoarthritis knee pain

* Flexion Therapeutics announces FDA approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis (OA) knee pain

Flexion's knee pain drug gets FDA nod

Oct 6 Flexion Therapeutics Inc said on Friday the U.S. Food and Drug Administration approved its drug, Zilretta, to treat moderate-to-severe osteoarthritis-related knee pain.

BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

* Flexion Therapeutics Inc - ‍on September 8, co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

Select another date: